FDA
-
-
-
-
-
-
-
LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in the Macau Special Administrative Region (SAR) of China
-
-
-
-
-
-
-
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
-
-
-
-
-
-
-
LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis
-
-
-
-
-
-
-
Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors
-
-
-
-
-
-
-
LianBio's (LIAN) Partner Tarsus Pharmaceuticals Announces Positive Topline Data from Second Pivotal Trial of TP-03
-
-
-
-
-
-
-
Tarsus Pharmaceuticals, Inc. Reports Full-Year 2021 Financial Results and Recent Business Achievements
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

